Eagle Health Investments LP Has $20.97 Million Stake in Ultragenyx Pharmaceutical Inc. $RARE

Eagle Health Investments LP increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 697,000 shares of the biopharmaceutical company’s stock after purchasing an additional 69,400 shares during the quarter. Ultragenyx Pharmaceutical accounts for 5.5% of Eagle Health Investments LP’s holdings, making the stock its 7th biggest holding. Eagle Health Investments LP’s holdings in Ultragenyx Pharmaceutical were worth $20,966,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at $35,765,000. Frontier Capital Management Co. LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $19,106,000. Aberdeen Group plc grew its holdings in Ultragenyx Pharmaceutical by 94.3% during the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock valued at $29,288,000 after purchasing an additional 472,600 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in Ultragenyx Pharmaceutical by 49.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock worth $35,768,000 after purchasing an additional 325,000 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth about $9,817,000. 97.67% of the stock is currently owned by institutional investors.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on RARE while lowering its price target from $60 to $50, signaling continued analyst conviction in the company’s upside despite the cut. HC Wainwright lowers PT but maintains Buy
• Positive Sentiment: Coverage pieces highlight Ultragenyx’s strong rare-disease pipeline and sizable upside potential, reinforcing longer-term bullish views that may attract investors focused on pipeline value. Pipeline-driven bullish coverage
• Neutral Sentiment: Wedbush reaffirmed a Neutral rating with a $25 price target, suggesting some analysts see limited near-term catalysts while others remain constructive — this creates mixed signals for traders. Wedbush reaffirms Neutral
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors to join a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering purchases from Aug 3, 2023 to Dec 26, 2025; the lead-plaintiff deadline is April 6, 2026 — this legal overhang can pressure the stock and increase perceived risk. KSF class action notice Rosen Law Firm notice Schall Law Firm notice Robbins Geller notice Kessler Topaz complaint Faruqi & Faruqi reminder
• Negative Sentiment: Ultragenyx announced a roughly 10% workforce reduction as it targets profitability in 2027; while cost cuts could improve longer-term margins, layoffs and execution risk typically weigh on near-term sentiment. Workforce reduction announcement

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RARE shares. Leerink Partners cut their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Truist Financial cut their price objective on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Robert W. Baird cut their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Finally, Jefferies Financial Group reduced their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.18.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $20.18 on Wednesday. The company has a 50 day moving average price of $26.27 and a 200-day moving average price of $29.66. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.41 and a fifty-two week high of $45.00. The stock has a market capitalization of $1.95 billion, a PE ratio of -3.46 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.00 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.The business’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period last year, the firm earned ($1.39) EPS. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the sale, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 6,227 shares of company stock worth $187,126 over the last 90 days. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.